Solid Biosciences Q3 net loss widens 18% to $53.95 million

PUBT · 10h ago
Solid Biosciences Q3 net loss widens 18% to $53.95 million
  • Solid Biosciences’ third-quarter 2026 net loss widened 18% year over year to $53.95 million.
  • Research and development expenses rose 12% to $43.6 million, while general and administrative expenses jumped 53% to $14.06 million.
  • Cash, cash equivalents and available-for-sale securities totaled $348.9 million at September 30, supporting an expected operational runway into the first half of 2028.
  • A late-fourth-quarter 2026 FDA meeting will address a potential accelerated approval pathway for Duchenne gene therapy SGT-003.
  • SGT-212 showed no treatment-related serious adverse events among five FALCON participants through November 3; initial data are expected in first-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041607PRIMZONEFULLFEED9870577) on November 04, 2026, and is solely responsible for the information contained therein.